(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 7.88% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Abbvie's revenue in 2026 is $64,386,000,000.On average, 35 Wall Street analysts forecast ABBV's revenue for 2026 to be $121,909,887,257,580, with the lowest ABBV revenue forecast at $116,225,070,951,735, and the highest ABBV revenue forecast at $126,357,721,463,925. On average, 35 Wall Street analysts forecast ABBV's revenue for 2027 to be $132,588,577,010,835, with the lowest ABBV revenue forecast at $122,796,980,134,650, and the highest ABBV revenue forecast at $140,185,414,219,050.
In 2028, ABBV is forecast to generate $142,760,104,103,295 in revenue, with the lowest revenue forecast at $131,623,730,973,225 and the highest revenue forecast at $153,032,356,881,000.